Developer docs
API playgroundTry for free, no card

Search company profiles

EpimAb Biotherapeutics

Full company profile

uuid0002611

Namestring
EpimAb Biotherapeutics
Legal namestring
EpimAb Biotherapeutics, Inc
Websiteurl
epimab.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

EpimAb Biotherapeutics is a privately held, clinical-stage biopharmaceutical company founded in 2015 and headquartered in Shanghai, China, with operating subsidiaries in Suzhou and Beijing and a Cayman Islands parent entity. The company develops multispecific antibody therapeutics for oncology and autoimmune diseases, anchored by its proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) bispecific platform, complemented by the MAT-Fab platform and the newly disclosed ProTCE (Prodrug T-Cell Engager) platform introduced at AACR 2026. FIT-Ig® combines two parental antibodies into a single tetravalent molecule with mAb-like manufacturability, solubility, and tissue penetration, avoiding Fc mutations, scFvs, linkers, and peptide connectors. Its clinical pipeline comprises three assets — EMB-01 (EGFR/cMET, Phase II), EMB-06 (BCMA/CD3, Phase I in autoimmune indications), and EMB-07 (ROR1/CD3, FDA IND cleared in 2025) — alongside more than ten preclinical candidates spanning tumor targeting, dual checkpoint regulators, and immune cell engagers.

The company makes money primarily through licensing and partnership agreements: it out-licenses the FIT-Ig® platform and pipeline assets to global pharmaceutical and biotechnology partners in exchange for upfront payments, development/regulatory/commercial milestones, and royalties. Named licensees and collaborators include Almirall (Spain, FIT-Ig® bispecifics, with the first CTA filed in February 2026), Juri Biosciences (worldwide license for a KLK2-directed T-cell engager in metastatic prostate cancer, May 2025), Vignette Bio (undisclosed targets, 2024), and Candid (sponsor of EMB-06 Phase I trials in SLE, gMG, and Thyroid Eye Disease, 2024). Go-to-market is conducted through dedicated business development outreach (partnering@epimab.com), participation in international partnering conferences, and scientific presentations. To date, EpimAb has raised approximately $219M+ across Seed, Series A ($25M, 2017), Series B ($74M, 2019), Series C ($120M, 2021), and 2022 convertible notes, sustaining a 51–100-person organization advancing assets through global clinical trials in the US, China, and Australia.

Short descriptiontext

EpimAb Biotherapeutics is a privately held, clinical-stage biopharmaceutical company developing bispecific and multispecific antibody therapeutics for oncology and autoimmune diseases using its proprietary FIT-Ig® platform, generating revenue through licensing and milestone-based partnerships with global pharmaceutical companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bispecific antibodies, immuno-oncology therapeutics, antibody drug development, clinical stage biopharmaceuticals, licensing partnerships
Industry2 codes
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Bispecific Antibody Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and partnership agreements
TypeLicensing Royalties
Description

EpimAb generates revenue through licensing its proprietary FIT-Ig® technology platform and pipeline assets to pharmaceutical partners. This includes upfront payments, milestone payments tied to development, regulatory, and commercial achievements, as well as royalties on net sales of licensed products.

epimab.com
2Research collaborations
TypeProfessional Services
Description

The company enters into research collaborations with partners like Candid, generating revenue through research funding and potential future licensing rights.

epimab.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1FIT-Ig
Description

Fabs-In-Tandem Immunoglobulin - proprietary bispecific antibody technology platform

epimab.com
+1 more record
Core offering1 text field

EpimAb Biotherapeutics is a clinical-stage biopharmaceutical company developing multispecific antibody therapeutics using its proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) and MAT-Fab platforms. The company generates revenue by licensing its bispecific antibody technology and pipeline assets to global pharmaceutical partners. Its pipeline includes three clinical-stage assets (EMB-01, EMB-06, EMB-07) and more than ten preclinical candidates across oncology and autoimmune disease indications.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

EpimAb Biotherapeutics is a clinical-stage biopharmaceutical company developing multispecific antibody therapeutics. The company's core proprietary technology platforms are FIT-Ig® (Fabs-In-Tandem Immunoglobulin) and MAT-Fab (Monovalent Asymmetric Tandem Fab), which generate bispecific molecules with antibody-like properties. The pipeline consists of 3 clinical-stage assets (EMB-01, EMB-06, EMB-07) and more than 10 preclinical candidates targeting strategic oncology areas including tumor targeting, dual checkpoint regulators, and immune cell engagers. The company also announced a novel ProTCE (Prodrug T-Cell Engager) platform in 2026.

Product and service6 records
1FIT-Ig® (Fabs-In-Tandem Immunoglobulin)
CategoryTechnology Platform
Description

Proprietary bispecific antibody platform that combines two parental antibodies into one molecule by rearranging DNA sequences into three genetic constructs co-expressed in mammalian cells; produces tetravalent bispecific antibodies with antibody-like manufacturability and solubility, licensed to pharmaceutical partners.

2MAT-Fab (Monovalent Asymmetric Tandem Fab)
CategoryTechnology Platform
Description

In-house bispecific platform technology used alongside FIT-Ig® to generate multispecific antibodies for therapeutic development and licensing.

3EMB-01 (EGFR/cMET)
CategoryClinical-Stage Therapeutic Candidate
Description

Clinical-stage bispecific antibody targeting EGFR and cMET for advanced or metastatic gastrointestinal cancers including colorectal cancer, hepatocellular carcinoma, gastric cancer, and biliary tract cancer.

4EMB-06 (BCMA/CD3)
CategoryClinical-Stage Therapeutic Candidate
Description

Clinical-stage T-cell engager targeting BCMA and CD3 for B-cell related autoimmune diseases including systemic lupus erythematosus (SLE) and generalized myasthenia gravis (gMG).

5EMB-07 (ROR1/CD3)
CategoryClinical-Stage Therapeutic Candidate
Description

Clinical-stage T-cell engager targeting ROR1 and CD3 for solid tumors and relapsed or refractory lymphoma including DLBCL.

6ProTCE Platform (Prodrug T-Cell Engager)
CategoryTechnology Platform
Description

Novel Prodrug T-Cell Engager platform enabling tumor-restricted activity of T-cell engagers, expanding EpimAb's multispecific antibody capabilities for oncology applications.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Juri Biosciences
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-05-27
Description

Juri Biosciences, a TCG Labs Soleil Portfolio Company, entered into a worldwide licensing agreement with EpimAb for KLK2-Directed T-Cell Engager in metastatic prostate cancer in May 2025. This represents a significant validation of EpimAb's T-cell engager technology and expands the company's pipeline into a new therapeutic area.

epimab.com
Strategic tierKeyTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-01-01
Description

Vignette Bio entered into a license agreement with EpimAb in 2024 for undisclosed targets, expanding the global reach of EpimAb's bispecific antibody technology.

Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

EpimAb established a research collaboration with Candid in 2024 for autoimmune disease programs. Candid is sponsoring ongoing Phase I trials in SLE (Systemic Lupus Erythematosus) and gMG (generalized Myasthenia Gravis), as well as TED (Thyroid Eye Disease).

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-01-01
Description

Almirall, a Spain-based dermatology-focused pharmaceutical company, entered into an option and evaluation agreement with EpimAb in 2023. Almirall filed the first CTA (Clinical Trial Application) for a FIT-Ig® bispecific antibody in February 2026, marking a significant milestone for the partnership and demonstrating clinical translation of EpimAb's technology platform.

5EpimAb Holdings (Cayman)
Strategic tierCoreTypeOthersAnnounced on2015-01-01
Description

Parent company incorporated in Cayman Islands in November 2021 (EpimAb Holdings). Original group founded in Cayman Islands in 2015.

epimab.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Genmab develops the DuoBody® bispecific antibody platform, the global commercial leader in bispecific antibody technology — the closest functional analog to EpimAb's FIT-Ig® platform. Both companies commercialize bispecific technology through licensing and co-development with major pharma.

TypeDirect peer
Description

Zymeworks operates the Azymetric™ and EFFECT™ platforms for bispecific and multispecific antibodies, with a similar business model of partnering pipeline and platform assets with large pharma — directly comparable in technology category and licensing-driven GTM.

TypeDirect peer
Description

Xencor's XmAb® bispecific and multispecific antibody platform and partnered pipeline (multiple pharma licensees) makes it a closely comparable platform-and-partnering biotech operating in the same technology category as EpimAb.

TypeDirect peer
Description

MacroGenics develops DART® and TRIDENT® bispecific/multispecific antibody platforms with clinical assets across oncology, employing a similar platform-plus-partnering model focused on immuno-oncology — directly comparable in therapeutic focus and modality.

TypeDirect peer
Description

Akeso is a Chinese clinical-stage biotech known for its in-house bispecific antibody pipeline (e.g., PD-1/VEGF, PD-1/CTLA-4) that is the closest geographic and strategic analog to EpimAb. Both are China-headquartered bispecific innovators advancing oncology assets through partnerships.

TypeBroad incumbent
Description

Innovent is a leading Chinese biopharmaceutical company with a broader biologics portfolio including bispecifics, antibodies, and ADCs. Comparable as a Chinese biologics innovator with global pharma partnerships, though it is more diversified beyond pure bispecifics.

TypeBroad incumbent
Description

Junshi is a Chinese clinical-stage biopharmaceutical developer with a broad oncology and immunology pipeline including bispecifics. Comparable as a China-based biologics innovator pursuing partnership strategies with major pharma for late-stage commercialization.

TypeBroad incumbent
Description

BeiGene is a major Chinese-founded biotech with a global commercial footprint and broad oncology pipeline. Operates in the same China biotech ecosystem and pursues similar biologic and immuno-oncology programs, though at a meaningfully larger scale than EpimAb.

TypeOthers
Description

Roche is a global pharma leader with the bispecific antibody Hemlibra (emicizumab) and a deep internal bispecific pipeline. Relevant as the dominant incumbent that EpimAb partners with or competes against for bispecific technologies and pipeline assets.

TypeBroad incumbent
Description

Lilly has active bispecific antibody programs (e.g., in oncology and immunology, with assets developed via acquisition of Loxo and other platforms) — relevant as a large pharma incumbent in the bispecific space that may compete for partner deals or look to license from platform companies like EpimAb.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EpimAb Biotherapeutics

Bispecific Antibody Therapeuticsepimab.com

EpimAb Biotherapeutics is a privately held, clinical-stage biopharmaceutical company developing bispecific and multispecific antibody therapeutics for oncology and autoimmune diseases using its proprietary FIT-Ig® platform, generating revenue through licensing and milestone-based partnerships with global pharmaceutical companies.

What EpimAb Biotherapeutics does

EpimAb Biotherapeutics is a privately held, clinical-stage biopharmaceutical company founded in 2015 and headquartered in Shanghai, China, with operating subsidiaries in Suzhou and Beijing and a Cayman Islands parent entity. The company develops multispecific antibody therapeutics for oncology and autoimmune diseases, anchored by its proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) bispecific platform, complemented by the MAT-Fab platform and the newly disclosed ProTCE (Prodrug T-Cell Engager) platform introduced at AACR 2026. FIT-Ig® combines two parental antibodies into a single tetravalent molecule with mAb-like manufacturability, solubility, and tissue penetration, avoiding Fc mutations, scFvs, linkers, and peptide connectors. Its clinical pipeline comprises three assets — EMB-01 (EGFR/cMET, Phase II), EMB-06 (BCMA/CD3, Phase I in autoimmune indications), and EMB-07 (ROR1/CD3, FDA IND cleared in 2025) — alongside more than ten preclinical candidates spanning tumor targeting, dual checkpoint regulators, and immune cell engagers.

The company makes money primarily through licensing and partnership agreements: it out-licenses the FIT-Ig® platform and pipeline assets to global pharmaceutical and biotechnology partners in exchange for upfront payments, development/regulatory/commercial milestones, and royalties. Named licensees and collaborators include Almirall (Spain, FIT-Ig® bispecifics, with the first CTA filed in February 2026), Juri Biosciences (worldwide license for a KLK2-directed T-cell engager in metastatic prostate cancer, May 2025), Vignette Bio (undisclosed targets, 2024), and Candid (sponsor of EMB-06 Phase I trials in SLE, gMG, and Thyroid Eye Disease, 2024). Go-to-market is conducted through dedicated business development outreach (partnering@epimab.com), participation in international partnering conferences, and scientific presentations. To date, EpimAb has raised approximately $219M+ across Seed, Series A ($25M, 2017), Series B ($74M, 2019), Series C ($120M, 2021), and 2022 convertible notes, sustaining a 51–100-person organization advancing assets through global clinical trials in the US, China, and Australia.

EpimAb Biotherapeutics firmographics

Firmographics
Name
EpimAb Biotherapeutics
Legal name
EpimAb Biotherapeutics, Inc
Website
https://epimab.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
EpimAb Biotherapeutics is a privately held, clinical-stage biopharmaceutical company developing bispecific and multispecific antibody therapeutics for oncology and autoimmune diseases using its proprietary FIT-Ig® platform, generating revenue through licensing and milestone-based partnerships with global pharmaceutical companies.
Ownership category
akta.pro rank

EpimAb Biotherapeutics industry classification

Industry
Product category
Bispecific Antibody Therapeutics
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Bispecific antibodies
  • Immuno-oncology therapeutics
  • Antibody drug development
  • Clinical stage biopharmaceuticals
  • Licensing partnerships

Where EpimAb Biotherapeutics is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices5 records

Markets served

EpimAb Biotherapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing and partnership agreements: EpimAb generates revenue through licensing its proprietary FIT-Ig® technology platform and pipeline assets to pharmaceutical partners. This includes upfront payments, milestone payments tied to development, regulatory, and commercial achievements, as well as royalties on net sales of licensed products.
  2. Research collaborations: The company enters into research collaborations with partners like Candid, generating revenue through research funding and potential future licensing rights.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

EpimAb Biotherapeutics product offering

Product offering

Core offering

EpimAb Biotherapeutics is a clinical-stage biopharmaceutical company developing multispecific antibody therapeutics using its proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) and MAT-Fab platforms. The company generates revenue by licensing its bispecific antibody technology and pipeline assets to global pharmaceutical partners. Its pipeline includes three clinical-stage assets (EMB-01, EMB-06, EMB-07) and more than ten preclinical candidates across oncology and autoimmune disease indications.

Product overview

EpimAb Biotherapeutics is a clinical-stage biopharmaceutical company developing multispecific antibody therapeutics. The company's core proprietary technology platforms are FIT-Ig® (Fabs-In-Tandem Immunoglobulin) and MAT-Fab (Monovalent Asymmetric Tandem Fab), which generate bispecific molecules with antibody-like properties. The pipeline consists of 3 clinical-stage assets (EMB-01, EMB-06, EMB-07) and more than 10 preclinical candidates targeting strategic oncology areas including tumor targeting, dual checkpoint regulators, and immune cell engagers. The company also announced a novel ProTCE (Prodrug T-Cell Engager) platform in 2026.

Differentiator

Problem solved

Functional benefit

Brands

  • FIT-Ig: Fabs-In-Tandem Immunoglobulin - proprietary bispecific antibody technology platform
  • MAT-Fab

Products and services

  • FIT-Ig® (Fabs-In-Tandem Immunoglobulin) Proprietary bispecific antibody platform that combines two parental antibodies into one molecule by rearranging DNA sequences into three genetic constructs co-expressed in mammalian cells; produces tetravalent bispecific antibodies with antibody-like manufacturability and solubility, licensed to pharmaceutical partners.
  • MAT-Fab (Monovalent Asymmetric Tandem Fab) In-house bispecific platform technology used alongside FIT-Ig® to generate multispecific antibodies for therapeutic development and licensing.
  • EMB-01 (EGFR/cMET) Clinical-stage bispecific antibody targeting EGFR and cMET for advanced or metastatic gastrointestinal cancers including colorectal cancer, hepatocellular carcinoma, gastric cancer, and biliary tract cancer.
  • EMB-06 (BCMA/CD3) Clinical-stage T-cell engager targeting BCMA and CD3 for B-cell related autoimmune diseases including systemic lupus erythematosus (SLE) and generalized myasthenia gravis (gMG).
  • EMB-07 (ROR1/CD3) Clinical-stage T-cell engager targeting ROR1 and CD3 for solid tumors and relapsed or refractory lymphoma including DLBCL.
  • ProTCE Platform (Prodrug T-Cell Engager) Novel Prodrug T-Cell Engager platform enabling tumor-restricted activity of T-cell engagers, expanding EpimAb's multispecific antibody capabilities for oncology applications.

Companies that use EpimAb Biotherapeutics

Customer profile

Segments3 records

Ideal customer profiles1 record

EpimAb Biotherapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

EpimAb Biotherapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and key.

  • Juri BiosciencescoreOEM/ Whitelabel/ Licensing Partner · 27 May 2025Juri Biosciences, a TCG Labs Soleil Portfolio Company, entered into a worldwide licensing agreement with EpimAb for KLK2-Directed T-Cell Engager in metastatic prostate cancer in May 2025. This represents a significant validation of EpimAb's T-cell engager technology and expands the company's pipeline into a new therapeutic area.
  • Vignette BiokeyOEM/ Whitelabel/ Licensing Partner · 1 January 2024Vignette Bio entered into a license agreement with EpimAb in 2024 for undisclosed targets, expanding the global reach of EpimAb's bispecific antibody technology.
  • CandidkeyStrategic or Co-development Partner · 1 January 2024EpimAb established a research collaboration with Candid in 2024 for autoimmune disease programs. Candid is sponsoring ongoing Phase I trials in SLE (Systemic Lupus Erythematosus) and gMG (generalized Myasthenia Gravis), as well as TED (Thyroid Eye Disease).
  • AlmirallcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2023Almirall, a Spain-based dermatology-focused pharmaceutical company, entered into an option and evaluation agreement with EpimAb in 2023. Almirall filed the first CTA (Clinical Trial Application) for a FIT-Ig® bispecific antibody in February 2026, marking a significant milestone for the partnership and demonstrating clinical translation of EpimAb's technology platform.
  • EpimAb Holdings (Cayman)coreOthers · 1 January 2015Parent company incorporated in Cayman Islands in November 2021 (EpimAb Holdings). Original group founded in Cayman Islands in 2015.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

EpimAb Biotherapeutics competitors and assessment

Company assessment

Direct peers

  • Genmab: Genmab develops the DuoBody® bispecific antibody platform, the global commercial leader in bispecific antibody technology — the closest functional analog to EpimAb's FIT-Ig® platform. Both companies commercialize bispecific technology through licensing and co-development with major pharma.
  • Zymeworks: Zymeworks operates the Azymetric™ and EFFECT™ platforms for bispecific and multispecific antibodies, with a similar business model of partnering pipeline and platform assets with large pharma — directly comparable in technology category and licensing-driven GTM.
  • Xencor: Xencor's XmAb® bispecific and multispecific antibody platform and partnered pipeline (multiple pharma licensees) makes it a closely comparable platform-and-partnering biotech operating in the same technology category as EpimAb.
  • MacroGenics: MacroGenics develops DART® and TRIDENT® bispecific/multispecific antibody platforms with clinical assets across oncology, employing a similar platform-plus-partnering model focused on immuno-oncology — directly comparable in therapeutic focus and modality.
  • Akeso: Akeso is a Chinese clinical-stage biotech known for its in-house bispecific antibody pipeline (e.g., PD-1/VEGF, PD-1/CTLA-4) that is the closest geographic and strategic analog to EpimAb. Both are China-headquartered bispecific innovators advancing oncology assets through partnerships.

Broad incumbents

  • Innovent Biologics: Innovent is a leading Chinese biopharmaceutical company with a broader biologics portfolio including bispecifics, antibodies, and ADCs. Comparable as a Chinese biologics innovator with global pharma partnerships, though it is more diversified beyond pure bispecifics.
  • Junshi Biosciences: Junshi is a Chinese clinical-stage biopharmaceutical developer with a broad oncology and immunology pipeline including bispecifics. Comparable as a China-based biologics innovator pursuing partnership strategies with major pharma for late-stage commercialization.
  • BeiGene: BeiGene is a major Chinese-founded biotech with a global commercial footprint and broad oncology pipeline. Operates in the same China biotech ecosystem and pursues similar biologic and immuno-oncology programs, though at a meaningfully larger scale than EpimAb.
  • Eli Lilly: Lilly has active bispecific antibody programs (e.g., in oncology and immunology, with assets developed via acquisition of Loxo and other platforms) — relevant as a large pharma incumbent in the bispecific space that may compete for partner deals or look to license from platform companies like EpimAb.

Others

  • Roche: Roche is a global pharma leader with the bispecific antibody Hemlibra (emicizumab) and a deep internal bispecific pipeline. Relevant as the dominant incumbent that EpimAb partners with or competes against for bispecific technologies and pipeline assets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

EpimAb Biotherapeutics social profiles

Digital presence

EpimAb Biotherapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EpimAb Biotherapeutics leadership team

Management profile

Number of profiles

Profiles5 records

EpimAb Biotherapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

EpimAb Biotherapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EpimAb Biotherapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EpimAb Biotherapeutics

What does EpimAb Biotherapeutics do?

EpimAb Biotherapeutics is a clinical-stage biopharmaceutical company developing multispecific antibody therapeutics using its proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) and MAT-Fab platforms. The company generates revenue by licensing its bispecific antibody technology and pipeline assets to global pharmaceutical partners. Its pipeline includes three clinical-stage assets (EMB-01, EMB-06, EMB-07) and more than ten preclinical candidates across oncology and autoimmune disease indications.

Is EpimAb Biotherapeutics a public or private company?

EpimAb Biotherapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was EpimAb Biotherapeutics founded?

EpimAb Biotherapeutics was founded in 2015. It employs 11 to 50 people.

Where is EpimAb Biotherapeutics based?

EpimAb Biotherapeutics is headquartered in Shanghai, China, in the Asia region.

How does EpimAb Biotherapeutics make money?

Two revenue lines are on record. Licensing and partnership agreements are the primary driver. The others are research collaborations.

Who are EpimAb Biotherapeutics's main competitors?

Direct peers on record are Genmab, Zymeworks, Xencor, MacroGenics and Akeso. Broad incumbents are Innovent Biologics, Junshi Biosciences, BeiGene and Eli Lilly. Roche is listed as an others.

Does EpimAb Biotherapeutics have an API?

No public API is recorded for EpimAb Biotherapeutics.

What industry is EpimAb Biotherapeutics in?

EpimAb Biotherapeutics's product category is Bispecific Antibody Therapeutics. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireEpimAb Biotherapeutics to Present a Novel Prodrug T-Cell Engager (ProTCE) Platform at the 2026 American Association for Cancer Research Annual MeetingEpimAb Biotherapeutics, a clinical-stage biotechnology company, will present its novel Prodrug T-Cell Engager (ProTCE) platform and candidate ProTCE EM33 at the 2026 AACR Annual Meeting in San Diego from April 17-22, 2026. The presentation will feature pre-clinical proof of concept data demonstrating potent and tumor-restricted activity of the platform. The CEO stated this achievement validates the company's global competitiveness and clinical translation potential, marking a key milestone in advancing its R&D capabilities.BioSpaceEpimAb Biotherapeutics to Present a Novel Prodrug T-Cell Engager (ProTCE) Platform at the 2026 American Association for Cancer Research Annual MeetingEpimAb Biotherapeutics will present its Prodrug T-cell engager (ProTCE) platform and candidate EM33 at the 2026 AACR Annual Meeting in San Diego. The poster, titled 'A novel and versatile Prodrug T cell engager platform with a novel candidate demonstrating potent and tumor-restricted activity,' will be presented on April 20, 2026. The company aims to advance the platform to address unmet medical needs.GlobeNewswireEpimAb Biotherapeutics Announces the First CTA Filing of a FIT-IG® Bispecific Antibody by its License Partner AlmirallAlmirall filed its first CTA for a bispecific antibody targeting IL-13 and OX-40L, developed under a 2023 license from EpimAb Biotherapeutics. The company expects to initiate First-in-Human Phase 1 in the first half of 2026. The partnership covers up to three undisclosed target pairs.GlobeNewswireEpimAb Biotherapeutics Announces Four Upcoming Presentations at the 2025 American Association for Cancer Research Annual MeetingEpimAb Biotherapeutics will present four poster presentations at the 2025 AACR Annual Meeting in Chicago, including clinical results for EMB-01 in colorectal cancer and preclinical data for three T-cell engagers. The company aims to leverage these results to advance novel therapies for diseases with unmet need.GlobeNewswireEpimAb Biotherapeutics Announces Oral Presentation for EMB-06 (CND106) First-in-human (FIH) Phase I Study in Multiple Myeloma at the American Society of Hematology (ASH) 2024 Annual MeetingEpimAb Biotherapeutics will present full Phase I results for EMB-06, a BCMA-targeting T cell engager, at the ASH 2024 Annual Meeting in San Diego. The oral presentation on December 8 will detail efficacy and safety in relapsed or refractory multiple myeloma patients. The company also granted exclusive rights outside Greater China to Candid Therapeutics.GlobeNewswireEpimAb Biotherapeutics Announces Upcoming Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)EpimAb Biotherapeutics will present two poster presentations at SITC 2024 in Houston, November 6-10, 2024. The posters cover preclinical results for a cMet x EGFR bispecific ADC and development data for an NK cell engager platform.PR NewswireChina Bispecific Antibody Market Opportunity & Clinical Trials Report 2022: 3 Antibodies Currently Approved with 3 to 4 Bispecific Antibodies Expected To Enter the Market Over Next 5 YearsResearchAndMarkets.com published a report on China's bispecific antibody market, noting that 3 antibodies (Blincyto, Hemlibra, Cadonilimab) are currently approved by China's National Medical Products Administration, with 3 to 4 more expected to enter the market over the next five years. China hosts over 250 ongoing clinical trials for bispecific antibodies, reflecting its emergence as a major global pharmaceutical market, while government incentives including tax exemptions and expedited 3-year approval timelines (versus 12 years in the US) are encouraging both domestic innovation and international partnerships. Key players including Akeso (which independently developed Cadonilimab), BeiGene (licensed by Amgen to commercialize Blincyto), Alphamab Oncology, and EpimAb are driving market growth through proprietary technology platforms and collaborations with Western companies.BioSpaceEpimAb Biotherapeutics Strengthens Scientific Advisory Board with Addition of Andrew X. ZhuEpimAb Biotherapeutics appointed Andrew X. Zhu, M.D., Ph.D., to its Scientific Advisory Board. Zhu is a hepatocellular carcinoma expert and Chief Scientific Officer at Jiahui Health. He will help advance EpimAb's bispecific antibody programs, including EMB-01, EMB-02, and EMB-06.AntibodysocietyFunding the Development of Antibody Innovations: Part 4: Exit Strategies for Investors in AntibodiesA final post in a series on antibody financing, by Sofinnova Partners partner Tom Burt and FUJIFILM Diosynth Biotechnologies' Nick Hutchinson, examines exit strategies for early-stage antibody investors. It notes crossover investors have accelerated paths to public markets, sometimes allowing preclinical companies to command higher valuations than later-stage peers. EpimAb is cited, having raised $25 million Series A, $74 million Series B and $120 million Series C.https://www.avcj.comCMB, Mirae lead Series C for China biotech player EpimAbShanghai-based EpimAb Biotherapeutics raised $120 million in Series C funding led by CMB International and Mirae Asset Financial Group. The company will use the funds to accelerate clinical trials on three antibody therapeutics, with EMB-01 entering phase-two trials.